Terms: = Kidney tumors AND PTEN, MMAC1, 5728, MGC11227, PTEN1, MHAM, P60484, BZS, ENSG00000171862 AND Treatment
72 results:
1. Deciphering the implications of mitophagy-related signatures in clinical outcomes and microenvironment heterogeneity of clear cell renal cell carcinoma.
Xiang J; Liu W; Liu S; Wang T; Tang H; Yang J
J Cancer Res Clin Oncol; 2023 Nov; 149(17):16015-16030. PubMed ID: 37689589
[TBL] [Abstract] [Full Text] [Related]
2. PI3K/Akt signaling in urological cancers: Tumorigenesis function, therapeutic potential, and therapy response regulation.
Rezaei S; Nikpanjeh N; Rezaee A; Gholami S; Hashemipour R; Biavarz N; Yousefi F; Tashakori A; Salmani F; Rajabi R; Khorrami R; Nabavi N; Ren J; Salimimoghadam S; Rashidi M; Zandieh MA; Hushmandi K; Wang Y
Eur J Pharmacol; 2023 Sep; 955():175909. PubMed ID: 37490949
[TBL] [Abstract] [Full Text] [Related]
3. Adaptive Immunity in Genitourinary Cancers.
Koti M; Bivalacqua T; Black PC; Cathomen T; Galsky MD; Gulley JL; Ingersoll MA; Kamat AM; Kassouf W; Siemens DR; Gao J
Eur Urol Oncol; 2023 Jun; 6(3):263-272. PubMed ID: 37069029
[TBL] [Abstract] [Full Text] [Related]
4. A machine learning framework develops a DNA replication stress model for predicting clinical outcomes and therapeutic vulnerability in primary prostate cancer.
Huang RH; Hong YK; Du H; Ke WQ; Lin BB; Li YL
J Transl Med; 2023 Jan; 21(1):20. PubMed ID: 36635710
[TBL] [Abstract] [Full Text] [Related]
5. A Phase I Study of Capivasertib in Combination With Abiraterone Acetate in Patients With Metastatic Castration-Resistant Prostate Cancer.
Shore N; Mellado B; Shah S; Hauke R; Costin D; Adra N; Cullberg M; Teruel CF; Morris T
Clin Genitourin Cancer; 2023 Apr; 21(2):278-285. PubMed ID: 36572571
[TBL] [Abstract] [Full Text] [Related]
6. Research Progress of PI3K/pten/AKT Signaling Pathway Associated with Renal Cell Carcinoma.
Fang Y; Ji W; Yan C
Dis Markers; 2022; 2022():1195875. PubMed ID: 36046376
[TBL] [Abstract] [Full Text] [Related]
7. Hypoxia-inducible factor pathway genes predict survival in metastatic clear cell renal cell carcinoma.
Tamukong PK; Kuhlmann P; You S; Su S; Wang Y; Yoon S; Gong J; Figlin RA; Janes JL; Freedland SJ; Halabi S; Small EJ; Rini BI; Kim HL
Urol Oncol; 2022 Nov; 40(11):495.e1-495.e10. PubMed ID: 35973929
[TBL] [Abstract] [Full Text] [Related]
8. The cancer-testis antigen a-kinase anchor protein 3 facilitates breast cancer progression via activation of the pten/PI3K/AKT/mTOR signaling.
Zhan CH; Ding DS; Zhang W; Wang HL; Mao ZY; Liu GJ
Bioengineered; 2022 Apr; 13(4):8478-8489. PubMed ID: 35322748
[TBL] [Abstract] [Full Text] [Related]
9. Phase II Trial of Cabozantinib Plus Nivolumab in Patients With Non-Clear-Cell Renal Cell Carcinoma and Genomic Correlates.
Lee CH; Voss MH; Carlo MI; Chen YB; Zucker M; Knezevic A; Lefkowitz RA; Shapnik N; Dadoun C; Reznik E; Shah NJ; Owens CN; McHugh DJ; Aggen DH; Laccetti AL; Kotecha R; Feldman DR; Motzer RJ
J Clin Oncol; 2022 Jul; 40(21):2333-2341. PubMed ID: 35298296
[TBL] [Abstract] [Full Text] [Related]
10. miR-96-5p targets pten to mediate sunitinib resistance in clear cell renal cell carcinoma.
Park SE; Kim W; Hong JY; Kang D; Park S; Suh J; You D; Park YY; Suh N; Hwang JJ; Kim CS
Sci Rep; 2022 Mar; 12(1):3537. PubMed ID: 35241735
[TBL] [Abstract] [Full Text] [Related]
11. Biomarker-Based Phase II Study of Sapanisertib (TAK-228): An mTORC1/2 Inhibitor in Patients With Refractory Metastatic Renal Cell Carcinoma.
McGregor BA; Xie W; Adib E; Stadler WM; Zakharia Y; Alva A; Michaelson MD; Gupta S; Lam ET; Farah S; Nassar AH; Wei XX; Kilbridge KL; Harshman L; Signoretti S; Sholl L; Kwiatkowski DJ; McKay RR; Choueiri TK
JCO Precis Oncol; 2022 Feb; 6():e2100448. PubMed ID: 35171658
[TBL] [Abstract] [Full Text] [Related]
12. Comprehensive analysis of pten-related ceRNA network revealing the key pathways WDFY3-AS2 - miR-21-5p/miR-221-3p/miR-222-3p - TIMP3 as potential biomarker in tumorigenesis and prognosis of kidney renal clear cell carcinoma.
Zhou X; Liu G; Xu M; Ying X; Li B; Cao F; Cheng S; Xiao B; Cheng M; Liang L; Jia M; Li W; Liu J; Li Z
Mol Carcinog; 2022 May; 61(5):508-523. PubMed ID: 35129856
[TBL] [Abstract] [Full Text] [Related]
13. Brusatol inhibits the growth of renal cell carcinoma by regulating the pten/PI3K/AKT pathway.
Wang T; Chen Z; Chen H; Yu X; Wang L; Liu X
J Ethnopharmacol; 2022 Apr; 288():115020. PubMed ID: 35066068
[TBL] [Abstract] [Full Text] [Related]
14. NUPR1 is a novel potential biomarker and confers resistance to sorafenib in clear cell renal cell carcinoma by increasing stemness and targeting the pten/AKT/mTOR pathway.
He W; Cheng F; Zheng B; Wang J; Zhao G; Yao Z; Zhang T
Aging (Albany NY); 2021 May; 13(10):14015-14038. PubMed ID: 34030133
[TBL] [Abstract] [Full Text] [Related]
15. Chromophobe renal cell carcinoma: New genetic and metabolic insights.
Zhang L; Henske EP
Urol Oncol; 2020 Aug; 38(8):678-681. PubMed ID: 32444178
[TBL] [Abstract] [Full Text] [Related]
16. pten Is Involved in Sunitinib and Sorafenib Resistance in Renal Cell Carcinoma.
Sekino Y; Hagura T; Han X; Babasaki T; Goto K; Inoue S; Hayashi T; Teishima J; Shigeta M; Taniyama D; Kuraoka K; Sentani K; Yasui W; Matsubara A
Anticancer Res; 2020 Apr; 40(4):1943-1951. PubMed ID: 32234883
[TBL] [Abstract] [Full Text] [Related]
17. Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive breast cancer (FAKTION): a multicentre, randomised, controlled, phase 2 trial.
Jones RH; Casbard A; Carucci M; Cox C; Butler R; Alchami F; Madden TA; Bale C; Bezecny P; Joffe J; Moon S; Twelves C; Venkitaraman R; Waters S; Foxley A; Howell SJ
Lancet Oncol; 2020 Mar; 21(3):345-357. PubMed ID: 32035020
[TBL] [Abstract] [Full Text] [Related]
18. MicroRNA-483-3p Promotes Proliferation, Migration, and Invasion and Induces Chemoresistance of Wilms' Tumor Cells.
Che G; Gao H; Tian J; Hu Q; Xie H; Zhang Y
Pediatr Dev Pathol; 2020; 23(2):144-151. PubMed ID: 31498707
[TBL] [Abstract] [Full Text] [Related]
19. pten expression and mutations in TSC1, TSC2 and MTOR are associated with response to rapalogs in patients with renal cell carcinoma.
Roldan-Romero JM; Beuselinck B; Santos M; Rodriguez-Moreno JF; Lanillos J; Calsina B; Gutierrez A; Tang K; Lainez N; Puente J; Castellano D; Esteban E; Climent MA; Arranz JA; Albersen M; Oudard S; Couchy G; Caleiras E; Montero-Conde C; Cascón A; Robledo M; Rodríguez-Antona C; García-Donas J;
Int J Cancer; 2020 Mar; 146(5):1435-1444. PubMed ID: 31335987
[TBL] [Abstract] [Full Text] [Related]
20. The evolving role of cytoreductive nephrectomy: incorporating genomics of metastatic renal cell carcinoma into treatment decisions.
Mano R; Gopal N; Hakimi AA
Curr Opin Urol; 2019 Sep; 29(5):531-539. PubMed ID: 31313716
[TBL] [Abstract] [Full Text] [Related]
[Next]
